Haematological Malignancies
Read Time: 9 mins

New Hematological Indications for Imatinib

Copy Link
Published Online: Aug 15th 2011 US Oncological Disease, 2007;1(2):36-9 DOI: https://doi.org/10.17925/OHR.2007.00.2.36
Authors: Srdan Verstovsek
Quick Links:
Article Information

Chronic myeloid leukemia (CML) is the only molecularly defined myeloid disorder to date and is distinguished by a unique chromosomal abnormality—the Philadelphia (Ph) chromosome—and expression of the BCR-ABL fusion oncoprotein.1 The treatment of CML was transformed by innovative molecularly targeted therapy, tyrosine kinase inhibitors (TKIs), namely imatinib mesylate (Gleevec®, Novartis). In addition to its inhibitory effect against cell proliferation induced by the constitutively active BCRABL TK in CML patients, imatinib is also an inhibitor of the KIT, ARG, and platelet-derived growth factor receptor (PDGFR) TKs. Imatinib is also indicated for the treatment of gastrointestinal stromal tumors that are associated with the mutated KIT TK; imatinib inhibits cell proliferation and induces apoptosis in the malignant cells. Some TKs, such as PDGFR, are active in disease pathways that underlie a number of rare hematological diseases. In October 2006, imatinib was approved for the treatment of five additional disorders, marking the first time that a single medicine has been approved for multiple indications simultaneously. The newly approved indications for rare and potentially life-threatening hematological diseases are listed in Table 1; these indications are based on a series of small clinical trials and multiple case studies presenting the efficacy of imatinib in the treatment of these diseases. Imatinib has been linked by its mechanism of action to the disease pathways of these rare hematological diseases; it is this connection and the discovery of shared molecular dysregulation that has made drug treatment with TKIs such as imatinib possible. The focus of this short article will be to address the rationale and the clinical evidence of efficacy for imatinib in the rare blood disorders myelodysplastic syndromes (MDS)/myeloproliferative diseases (MPDs), hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia(CEL), and aggressive systemic mastocytosis (ASM).

Myelodysplastic Syndromes/Myeloproliferative Diseases
MDS and MPDs are distinct disorders. However, in certain cases, there can be an overlap of clinical and/or morphological features that are traditionally associated with either MDS or MPD alone, thus diagnosis may be more challenging. This overlap led to World Health Organization (WHO) reclassification of hematopoietic and lymphoid neoplasms andthe recognition of a new separate category of MDS/MPD,2 which includes chronic myelomonocytic leukemia (CMML), atypical CML (aCML), juvenile myelomonocytic leukemia (JMML), and MDS/MPD unclassifiable (MDS/MPD-U). MDS/MPD is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by the overproduction ofcertain myeloid cells in the bone marrow that are abnormal in appearance, ‘out of shape,’ or dysplastic. Of all the chromosomal abnormalities detected in MDS/MPD patients, over half are due to deletions in chromosomes 5, 7, 11, 12, 13, and 20.3 A small proportionof MDS/MPD patients have a chromosomal breakpoint on chromosome 5 (5q33), causing constitutive activation of the PDGFRβ gene coding for a PDGFRβ TK.4 Others may have a chromosomal breakpoint on chromosome 4 (4q12), causing activation of a gene for PDGFRα TK. It is believed that these TKs are responsible for the disease in these patients, and they are particularly sensitive to imatinib. Cytogenetic testing is mandatory for all patients with MDS/MPD.5 Additionally, since MDS/MPD may be associated with high eosinophil levels, cytogenic testing may helpto distinguish MDS/MPD from HES.

CMML is distinguished from CML by the absence of the Ph chromosome and the BCR-ABL transcript.6 Under the new WHO classification, CMML is divided into two subcategories—CMML-1 and CMML-2—based on number of blast cells in the blood and bone marrow, because of the relationship between blast-cell number and prognosis.2The median age at diagnosis is 73 years and survival is dependent on disease severity, with a median survival time of 12–24 months.7 Abnormal clonal myeloid proliferation in CMML often progresses to acute myeloid leukemia (AML). The symptoms of aCML are similar to those of CML; however, aCML patients are Ph-chromosome-negative. Furthermore, aCML is associated with granulocyte and multilineage dysplasia, which is not found in CML. aCML can be distinguished from CMML by the presence of a higher percentage (>15%) of circulating immature granulocytes. The disease is very aggressive and median survival time is 11–18 months.8

Current Treatment Options
Currently, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for CMML; however, many patients with CMML are not eligible for HSCT due to advanced age or comorbid conditions. CMML can also be treated with standard chemotherapy of hydroxyurea with supportive care. Topotecan and cytarabine have also been found to be effective in generating hematological and cytogenetic responses in patients with CMML.9 Hematopoietic growth factors, particularly erythropoietin, may be of benefit for some CMML patients.6 aCML can also be treated with standard chemotherapy of hydroxyurea, interferon-α, and busulfan; however, this regimen is associated with poor outcome. In comparison, allogeneic HSCT has an estimated survival rate of 89% for patients with aCML.10

Rationale and Clinical Evidence for Imatinib
Imatinib has been approved for the treatment of adults with forms of MDS/MPD associated with PDGFR gene rearrangements. PDGFR gene rearrangements result from translocations involving chromosome 5q33 and 4q12; therefore, confirmation of these translocations should support the use of imatinib in MDS/MPD patients. CMML and aCML are two MDS/MPD disorders associated with specific PDGFR gene rearrangements that lead to aberrant PDGFR signaling and hematopoietic transformation. Translocations involving the PDGFRβ gene on chromosome 5 have been associated with MDS/MPD, and many fusion partners have been identified to date.11 In these patients, the PDGFRβ gene has served as a distinct marker in predicting response to imatinib therapy.12 Imatinib induces durable clinical responses in MPDs associated with PDGFRβ.4,13–15 One of the larger studies showed that with imatinib therapy blood counts underwent rapid normalization in 11 of 12 patients.14 Several case studies have confirmed the therapeutic benefits of imatinib therapy in PDGFRβ-rearranged MPD regardless of the fusion gene partner.15–19 The data presented to the US Food and Drug Administration (FDA) include a phase II study of seven MDS/MPD patients and an additional 24 patients from a number of case reports and clinical studies treating patients with 400mg imatinib daily. Complete hematological and major cytogenetic response was achieved in 14 (45%) and 12 (39%) of these 31 patients, respectively; 10 patients achieved a complete cytogenetic response. All 17 patients found to possess a PDGFR gene rearrangement responded hematologically, and 13 (81%) had a complete hematological response. None of the 14 patients lacking a PDGFR gene rearrangement responded cytogenetically, although one (7%) achieved a complete hematological response.20 The recommended dosage for adult patients with MDS/MPD is 400mg imatinib daily,20 but responses to lower doses have been observed.21

Hypereosinophilic Syndrome/ Chronic Eosinophilic Leukemia
HES refers to a group of myeloproliferative disorders characterized by the persistent overproduction and elevated levels of eosinophils in blood (>1,500 cells/μl) with symptoms of organ involvement, including valvular disease, cardiomyopathy, sensorimotor isolated central nervous system (CNS) vasculitis, optic neuritis, pulmonary infiltrates, gastroenteritis, sclerosing cholangitis, cytopenias, bone marrow fibrosis, and thrombotic angiopathy.22–25 Primarily affecting males, HES has a reported 10-year survival rate of less than 50%.26 Patients previously diagnosed with idiopathic HES can be divided into at least three distinct subgroups. The first are those patients reclassified as having ‘clonal’ eosinophilia (CEL) because of the identification of the FIP1L1-PDGFRα fusion transcript.27–30 Second, there are patients with HES in whom no evidence of clonality can be demonstrated; these patients must be considered idiopathic and may have disease that ultimately evolves into acute leukemia or aggressive forms of MPDs.31 The third subset of patients carry an abnormal T-cell population (helper Th2 lymphocytes) that produces interleukin-5 (IL-5), a cytokine required for the growth and differentiation of eosinophils.31

Diagnosis of HES is based on sustained eosinophilia (>1,500 cells/μl) for more than six months in the absence of other causes of eosinophilia such as parasitic infections and allergies.32 HES patients with a deletion in chromosome 4, which fuses the FIP1-like-1 gene (FIP1L1) to the PDGFRαgene, are now reclassified as CEL, as the resulting FIP1L1-PDGFRα rearrangement gene has become a marker of disease clonality.27–30 The new fusion gene leads to constitutive activation of the PDGFRα TK.32 This can be effectively negated through treatment with imatinib, the treatment of choice for these patients. Proper testing for the FIP1L1- PDGFRα rearrangement is highly recommended in all patients with suspected HES/CEL. Other patients with HES/CEL may have a chromosomal abnormality with a breakpoint at a site where genes for PDGFR TKs are found (4q12 and 5q33 for PDGFRα and β, respectively). These TKs are constitutively active in these cases and are sensitive to imatinib therapy. Cytogenetic testing is highly recommended for patients with suspected HES/CEL.

Current Treatment Options
Asymptomatic HES patients lacking evidence of organ damage are closelymonitored in lieu of treatment, although there is no general consensus on how to treat them.24 The first-line treatment of HES has traditionally been prednisone, with a response rate of nearly 70%.33 However, relapses often occur upon cessation of therapy, requiring the patient to seek alternative drug options, such as interferon-α or hydroxyurea, considered now to be the second-line drugs of choice.25

Rationale and Clinical Evidence for Imatinib
Among the recent FDA approvals was the indication of imatinib for the treatment of adults with HES/CEL associated with FIP1L1-PDGFRα fusion kinase—identified by mutational analysis or fluorescence in situ hybridization (FISH) demonstration of CHIC2 allele deletion—and for patients with HES/CEL who are FIP1L1-PDGFRα fusion kinase-negative or unknown. The incidence of the FIP1L1-PDGFRα fusion kinase mutation has not been firmly established, and may be less common than initially anticipated. The prevalence has been conveyed in multiple reports to range anywhere between 3 and 56%, with most studies reporting a frequency of 10–15%.34,35 The fusion gene also has a distinct male preponderance.36,37 Cases of HES/CEL with the FIP1L1-PDGFRα rearrangement have been established to have high sensitivity to imatinib, with an overall rate of complete hematological remission of over 95% across 73 reported cases.17,32,38–44 Patients expressing the FIP1L1-PDGFRα fusion gene experienced rapid complete hematological remission within three months in 100% of patients (15/15). Complete molecular remission, defined as a negative nested reverse transcriptase polymerase chain reaction (RT-PCR) for FIP1L1-PDGFRα fusion transcripts in peripheral blood, was seen within six months in 83% (10/12) of FIP1L1- PDGFRα-positive patients.45 In contrast, of the 14 patients lacking this marker, only three (21%) responded to imatinib, while six (43%) achieved partial or complete clinical and hematological responses.45 HES/CEL patients have shown durable remission of up to five years when treated with imatinib (100–400mg daily).28 Twenty-one FIP1L1- PDGFRα-positive HES/CEL patients achieved a complete hematological response in less than one month.28 All of these patients remained in complete hematological remission with a median follow-up of 28 months (range 13–67).28 Other studies have documented complete hematological responses in at least 13 of 69 patients (19%) lacking the fusion gene,17,32,38–44 as well as partial responses.46,47 It appears that although imatinib is less effective in HES without the FIP1L1-PDGFRα marker, the drug may also have a non-specific myelosuppressive effect.35 With this in mind, HES patients should be analyzed for the presence of the FIP1L1- PDGFRα- rearrangement prior to commencing therapy to assess the efficacy of ensuing imatinib treatment. The recommended dosage of imatinib in HES/CEL patients is 400mg daily. However, a daily starting dosage of 100mg imatinib is recommended for HES/CEL patients with the FIP1L1-PDGFRα rearrangement, with the possibility of increasing dosage to 400mg daily in the absence of adverse effects or insufficient response to drug therapy.20

Aggressive Systemic Mastocytosis
SM is a heterogeneous group of disorders characterized by clonal expansion of mast cells and their excessive accumulation in variousorgans such as skin, bone marrow, gastrointestinal tract, lymph nodes, liver, and spleen. The clinical course can range from no/minimal symptoms to diffuse systemic involvement with a multitude of symptoms. When the involvement of an organ with the disease affects its function, the disease is considered to be aggressive, or ASM, and prognosis is poor. KIT is a receptor for stem cell factor that is expressed by mast cells at varying developmental stages; its deregulation is thought to play a role in mast cell proliferation.48,49

A great majority of SM patients exhibit a mutation in the c-kit oncogene, resulting in ligand-independent mast cell growth through autophosphorylation of the KIT TK. The D816V mutation is the most common KIT mutation, but is insensitive to imatinib. Sporadic cases of alternative KIT mutations have been described, which are usually imatinib-sensitive.50 Proper testing for KIT mutational status in patientssuspected of having SM is highly suggested; positive results help to confirm the diagnosis (it is part of the diagnostic criteria) and may help the physician to select proper therapy. A subgroup of patients, usually those with associated eosinophilia, has also been found to express theimatinib-sensitive FIP1L1-PDGFRα rearrangement gene.38 Patients with ASM and associated eosinophilia should undergo proper testing to document the presence of the FIP1L1-PDGFRα rearrangement.

Current Treatment Options
Interferon-α and cladribine have traditionally been the first-line therapeutic agents used in the treatment of ASM. Though reported to improve symptoms of ASM, interferon-α has a low response rate— ranging from 30 to 50%—and multiple adverse effects. Cladribine has shown therapeutic activity in ASM as well, but myelosuppression occurs in approximately one-third of cases.24

Rationale and Clinical Evidence for Imatinib
Imatinib is approved for the treatment of adults with ASM who either lack the D816V KIT mutation or are of unknown KIT mutational status. The D816V mutation, responsible for function activity in the KIT TK, has been reported to be present in over 90% of ASM cases,51 while another study has shown a much lower incidence of the mutation (31%).52 Although imatinib can inhibit wildtype KIT through binding, it is unable to interact with mast cell lines expressing the D816V variant.51,53 However, ASM patients with mutations elsewhere in ckit have shown clinical responses to imatinib.54,55 SM may be accompanied by clonal eosinophilia, and half of these patients have the FIP1L1-PDGFRα fusion kinase. These patients have been shown to obtain complete clinical responses under imatinib therapy.56,57 Case studies and phase II clinical data involving 28 patients with ASM receiving 100–400mg imatinib daily were presented to the FDA. Only one of the four patients carrying the D816V mutation responded to imatinib treatment with a complete hematological response, but this patient also had concomitant CML. The two patients with juxtamembrane mutations in KIT experienced a partial hematological response, while only seven of 15 patients (44%) of unknown KIT mutational status displayed this response. Of the seven patients carrying the FIP1L1-PDGFRα rearrangement, all were found to achieve complete hematological response.20 The recommended dosage of imatinib is 400mg daily. A starting dosage of 100mg daily is recommended for patients with ASM associated with eosinophilia, with the possibility of increasing dosage to 400mg daily in the absence of adverse effects or insufficient response to drug therapy.20

Molecularly targeted therapies have been successful in treating myeloid disorders, largely through the activities of TKIs. Through potent inhibition of a number of TKs, imatinib has been newly indicated for the treatment of PDFGR-rearranged MDS/MPD, HES/CEL, and ASM without the D816V c-kit mutation or with unknown mutational status. The success of this targeted drug therapy in the aforementioned rare hematological diseases was possible only through increasing knowledge of disease pathways. The multi- indication approval for imatinib has immense implications in the development of disease treatment. The use of TKIs in chronic and acute leukemias has led to the discovery of new targets in other diseases, such as the PDGFR gene rearrangements. The efficacy of imatinib against multiple diseases stems from the drug’s ability to act against common molecular pathways and emphasizes a new approach to drug development, as cancers and diseases with varying origins and locations can respond similarly tocertain drug treatments due to shared disease pathways. The continued search for novel targets and ever-expanding knowledge about the molecular pathogenesis of hematological malignancies will likely lead to growth in the area of molecularly targeted therapy.

Editorial assistance for this manuscript was provided by Touch Briefings andNovartis Pharmaceuticals Corp.


  1. Tefferi A, Elliott MA, Pardanani A, Atypical myeloproliferative disorders: diagnosis and management, Mayo Clin Proc, 2006;81:553–63.
  2. Jaffe ES, Harris NE, Stein H, Vardiman JW (eds), World Health Organization classification of tumors: Pathology and Genetics of tumours of the haematopoietic and lymphoid tissues, Lyon, France: International Agency for Research on Cancer (IARC) Press, 2001
  3. Hirai H, Molecular mechanisms of myelodysplastic syndrome, Jpn J Clin Oncol, 2003;33(4):153–60.
  4. Apperley JF, Gardembas M, Melo JV, et al., Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta, N Engl J Med, 2002;347(7):481–7.
  5. Steer EJ, Cross NC, Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the plateletderivedgrowth factor receptor beta, Acta Haematol, 2002;107:113–22.
  6. Cortes J, CMML: a biologically distinct myeloproliferative disease, Curr Hematol Rep, 2003;2:202–8.
  7. Germing U, Strupp C, Knipp S, et al., Chronic myelomonocytic leukemia in the light of the WHO proposals, Haematologica, 2007;92:974–7.
  8. Hernandez JM, del Canizo MC, Cuneo A, et al., Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia, Ann Oncol, 2000;11:441–4.
  9. Onida F, Beran M, Chronic myelomonocytic leukemia: myeloproliferative variant, Curr Hematol Rep, 2004;3:218–26.
  10. Koldehoff M, Beelen DW, Trenschel R, et al., Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukaemia, Bone Marrow Transplant, 2004;34(12):1047–50.
  11. Walz C, Metzgeroth G, Haferlach C, et al., Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene, Haematologica, 2007;91:163–9.
  12. David M, Cross NC, Burgstaller S, et al., Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCRABL- negative chronic myeloproliferative disorders, Blood, 2007;109:61–4.
  13. Wilkinson K, Velloso ER, Lopes LF, et al., Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib, Blood, 2003;102(12):4187–90.
  14. Jones AV, Cross NC, Oncogenic derivatives of platelet-derived growth factor receptors, Cell Mol Life Sci, 2004;61:2912–23.
  15. Lierman E, Cools J, ETV6 and PDGFRB: a license to fuse, Haematologica, 2007;92(02)145–7.
  16. Magnusson MK, Meade KE, Nakamura R, et al., Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene, Blood, 2002;100:1088–91.
  17. Pardanani A, Tefferi A, Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders, Blood, 2004;104(7):1931–9.
  18. Pitini V, Arrigo C, Teti D, et al., Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report, Haematologica, 2003;88:ECR18.
  19. Wittman B, Horan J, Baxter J, et al. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate, Leuk Res, 2004;28(Suppl. 1):65–9.
  20. Gleevec® (imatinib mesylate) tablets prescribing information, East Hanover, NJ: Novartis Pharmaceuticals Corporation, Nov 2006.
  21. Reiter A, Grimwade D, Cross NC, Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders, Haematologica, 2007;92(9): 1153–8.
  22. Brito-Babapulle F, The eosinophilias, including the idiopathichypereosinophilic syndrome, Br J Haem, 2003;121:20–23.
  23. Weller PF, Bubley GJ, The idiopathic hypereosinophilic syndrome, Blood, 1994;83:2759–79
  24. Pardanani A, Verstovsek S, Hypereosinophilic syndrome, chronic eosinophilic leukaemia and mast cell disease, Cancer J, 2007;13(6):384–91.
  25. Tefferi A, Patnaik MM, Pardanani A, Eosinophilia: secondary, clonal and idiopathic, Br J Haem, 2006;133:468–92.
  26. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases, Ann Med Interne (Paris), 1989;140:253–7.
  27. Bain B, The idiopathic hypereosinophilic syndrome and eosinophilic leukemias, Haematologica, 2004;89:133–7.
  28. Rondoni M, Ottaviani E, Piccaluga PP, et al., FIP1L1-PDGFRalpha positive hypereosinophilic syndrome (HES). The response to imatinib (IM) is durable. A Report of 21 patients with a follow-up of 12 to 67 months, Blood, 2006;108: abstract 2700.
  29. Gotlib J, Molecular classification and pathogenesis of eosinophilic disorders: 2005 update, Acta Haematol, 2005;114:7–25.
  30. Chang HW, Leong KH, Koh DR, Lee SH, Clonality of isolated eosinophils in the hypereosinophilic syndrome, Blood, 1999;93:1651–7.
  31. Kalac M, Quintás-Cardama A, Vrhovac R, et al., A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia, Cancer, 2007;110(5):955–64.
  32. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome, N Engl J Med, 2003;348:1201–14.
  33. Parrillo JE, Fauci AS,Wolff SM, Therapy of the hypereosinophilic syndrome, Ann Intern Med, 1978;89:167–72.
  34. Jovanovic JV, Score J,Waghorn K, et al., Low-dose imatinib mesylate leads to rapid induction of major molecular responsesand achievement of complete molecular remission FIP1L1- PDGFRA positive chronic eosinophilic leukaemia, Blood, 2007;109:4635–40.
  35. Pardanani A, Ketterling RP, Li CY, et al., FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature, Leuk Res, 2006;30(8):965–70.
  36. La Starza P, Specchia G, Cuneo A, et al., The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases, Haematologica, 2005;90:596–601.
  37. Vandenberghe P, Wlodarska I, Michaux L, et al., Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias, Leukemia, 2004;18:734-42.
  38. Pardanani A, Ketterling RP, Brockman SR, et al., CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy, Blood, 2003;102:3093–6.
  39. Baccarani M, Cilloni D, Rondoni M, et al., The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospectivestudy, Haematologica, 2007;92(9)1173–9.
  40. Klion AD, Robyn J, Akin C, et al., Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome, Blood, 2004;103:473–8.
  41. Rose C, Dupire S, Roche-Lestienne C, et al., Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft, Leukemia,2004;18:354–5.
  42. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al., Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics, Leukemia, 2005;19:792–8.
  43. Helbig G, Stella-Holowiecka B, Grosicki S, et al., The results of imatinib therapy for patients with primary eosinophilic disorders, Eur J Haematol, 2006;76:535–6.
  44. Muller Am, Martens UM, Hofmann SC, et al., Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature, Ann Hematol, 2006;85:1–16.
  45. Metzgeroth G, Popp H,Walz C, et al., A phase-II-study to evaluate efficacy and safety of imatinib in eosinophilia-associated myeloproliferative disorders and idiopathic hypereosinophilic syndrome, Blood, 2006;108: abstract 671.
  46. Martinelli G, Cilloni D, Ottaviani E, et al., Idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRArearrangement can be effectively treated with imatinib, Blood, 2004;104:1504.
  47. Pardanani A, Brockman SR, Paternoster SF, et al., FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia, Blood,2004;104(10)3038–45.
  48. Guilhot F, Indications for imatinib mesylate therapy and clinical management, Oncologist, 2004;9:271–81.
  49. Kanbe T, Soma Y, Kawa Y, et al., Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity, Br J Dermatol, 2001;144:1148–53.
  50. Droogendijk HJ, Kluin-Nelemans HJ, Doormaal JJ, et al., Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial, Cancer, 2006;107(2):345–51.
  51. Akin C, Targeting the mast cell: beyond KIT, Blood, 2007;109(7):2674–5.
  52. Pardanani A, Reeder TL, Kimlinger TK, et al., Fit-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease, Leuk Res, 2003;27:739–52.
  53. Patnaik MM, Rindos M, Kouides PA, et al., Systemic mastocytosis: a concise clinical and laboratory review, Arch Pathol Lab Med, 2007;131:784–91.
  54. Akin C, Fumo G, Yavuz AS, et al., A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib, Blood, 2004;103:322–5.
  55. Zhang LY, Smith ML, Schultheis B, et al., A novel K509I mutation of KIT identified in familial mastocytosis—in vitro and in vivo responsiveness to imatinib therapy, Leuk Res, 2006;30:373–8.
  56. Pardanani A, Ketterling RP, Brockman SR, et al., CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemicmastocytosis associated with eosinophilia and predicts response to imatinib therapy, Blood, 2003;102:3093–6.
  57. Tefferi A, Verstovsek S, Pardanani A, How we diagnose and treat WHO-defined systemic mastocytosis in adults, Haematologica, 2008;93(1):6–9.

Further Resources

Share this Article
Related Content In Haematological Malignancies
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72